Northpointe Capital’s AbbVie ABBV Stock Holding History

Northpointe Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-21,484	Closed	-$2.03M	–	172
2018 Q3	$2.03M	Buy	+21,484	New	+$2.04M	0.29%	148

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northpointe Capital's ABBV Position: Q4 2018 in Review

Northpointe Capital sold out of AbbVie (ABBV) in Q4 2018, closing a stake of 21,484 shares — an estimated $2.03M sold.

Northpointe Capital first reported a position in ABBV in Q3 2018 and held it in 1 quarter. The position peaked at $2.03M in Q3 2018. 2,062 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

Northpointe Capital reported no remaining AbbVie position as of Q4 2018 after selling out during the quarter.
Northpointe Capital sold 21,484 AbbVie shares in Q4 2018, an estimated $2.03M.
Northpointe Capital first reported a position in AbbVie in Q3 2018 and held it in 1 quarter.
Northpointe Capital's AbbVie position peaked at $2.03M in Q3 2018.
2,062 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Northpointe Capital's 13F filing for Q4 2018, filed 24 Jan 2019.